Merck signs deal with Jiangsu Hengrui for access to heart drug

Merck signs $2 billion deal with Jiangsu Hengrui Pharmaceuticals for access to experimental heart disease drug. HRS-5346, an oral small molecule inhibitor of Lp(a) formation, is being evaluated in a Phase 2 clinical trial in China. Merck will pay an upfront fee of $200 million and up to $1.77 billion in milestone payments, while Hengrui […]